Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Aranesp · 4 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Aranesp |
| Name | Type | Description |
|---|---|---|
| Aranesp® | DRUG | - |
| Aranesp® (darbepoetin alfa) | DRUG | - |
| Aranesp | DRUG | Aranesp |
Inclusion Criteria: -at least 18 years old - Diagnosis of chronic kidney disease (CKD) and receiving dialysis for at least 3 months prior to screening - Baseline Hb level greater than or equal to 10.0 g/dL and less than or equal to 13.0 g/dL - Adequate iron stores (defined as serum ferritin greater ...
Top 20 of 25 competitors
Aranesp is used for anemia associated with chronic kidney disease and chemotherapy-induced anemia in cancer patients. It has been studied in prostate cancer patients with anemia. Aranesp is developed by Amgen Inc. for these indications.
Aranesp targets the erythropoietin receptor, stimulating red blood cell production. It is a small molecule designed to treat anemia by promoting erythropoiesis. This mechanism addresses anemia in chronic kidney disease and cancer patients.
Aranesp is developed by Amgen Inc., a biopharmaceutical company. Amgen's stock ticker is AMGN. The company has conducted clinical trials for Aranesp in kidney disease, anemia, and prostate cancer.
Aranesp is in Phase 2 clinical development for prostate cancer and anemia. It has completed Phase 3 trials for chronic kidney disease. The drug is investigational and not approved for these indications.
Aranesp has completed trials including NCT00116701 and NCT00124098 for kidney disease, NCT00144131 for chemotherapy-induced anemia, and NCT00245895 for prostate cancer anemia. These trials enrolled a total of 750 patients.
Yes, Aranesp is the brand name for darbepoetin alfa. Clinical trials such as NCT00144131 refer to darbepoetin alfa in their titles, confirming that Aranesp and darbepoetin alfa are the same drug.